Randomization to Once-Daily Stavudine Extended Release/Lamivudine/Efavirenz Versus a More Frequent Regimen Improves Adherence While Maintaining Viral Suppression

REFERENCES

• Kress KD. HIV update: emerging clinical evidence and a review of recommendations for the use of highly active an-tiretroviral therapy. Am J Health Syst Pharm. 2004;61\(suppl 3):S3–S14.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among subjects with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Holtzer CD, Roland M. The use of combination antiretro-viral therapy in HIV-infected patients. Ann Pharmacother 1999;33:198–209.
   PubMed Web of Science ®Google Scholar
• Vittinghoff E, Scheer S, O'Malley P, et al. Combination an-tiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis. 1999;179:717–720.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observa-tional study. Lancet. 2003;362:22–29.
   PubMed Web of Science ®Google Scholar
• Sethi AK, Celentano DD, Gange SJ, et al. Association be-tween adherence to antiretroviral therapy and human im-munodeficiency virus drug resistance. Clin Infect Dis. 2003; 37:1112–1118.
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223–231.
   PubMed Web of Science ®Google Scholar
• Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007; 146:564–573.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr J, et al. Adherence to pro-tease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
   PubMed Web of Science ®Google Scholar
• Lucas GM, Wu AW, Cheever LW. Adherence to antiretrovi-ral therapy: an update of current concepts. Curr HIV/AIDS Rep. 2004;1:172–180.
   PubMedGoogle Scholar
• Roge BT, Barfod TS, Kirk O, et al. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. HIV Med. 2004;5:344–351.
   PubMed Web of Science ®Google Scholar
• Stone VE, Jordan J, Tolson J, et al. Perspectives on adher-ence and simplicity for HIV infected patients on antiretrovi-ral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004;36:808–816.
   PubMed Web of Science ®Google Scholar
• Vervoort S, Borleffs J, Hoepelman A, et al. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS. 2007;21:271–281.
   PubMed Web of Science ®Google Scholar
• Fortin C, Joly V. Efavirenz for HIV-1 infection in adults: an overview. Expert Rev Anti Infect Ther 2004;2:671–684.
   PubMedGoogle Scholar
• Frampton JE, Croom KF. Efavirenz/emtricitabine/tenofo-vir disoproxil fumarate: triple combination tablet. Drugs. 2006;66:1501–1512.
   PubMed Web of Science ®Google Scholar
• Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in anti-retroviral-näfve patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 2006;43:535–540.
   PubMed Web of Science ®Google Scholar
• Riddler S, Haubrich R, DiRienzo G, et al. A prospective, randomized phase III trial of NRTI-, Pl-, and NNRTI-sparing regimens for initial treatment of HIV-1. ACTG 5142. Pre-sented at: 16th International AIDS Conference; August 13–18, 2006; Toronto, Canada.
   Google Scholar
• Ruane P, Lang J, DeJesus E, et al. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection. HIV Clin Tri-als. 2006;7:229–236.
   PubMed Web of Science ®Google Scholar
• Fischl MA, Collier AC, Mukherjee AL, et al. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS. 2007;21:325–333.
   PubMed Web of Science ®Google Scholar
• Scherpbier HJ, Bekker V, Pajkrt D, et al. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. Pediatrics. 2007;119:705–715.
   PubMed Web of Science ®Google Scholar
• Brett-Smith H, Reynolds L, Bessen L, Rutkiewicz V. Two-year analysis of stavudine extended-release/prolonged release capsules (XR/PRC) as compared to stavudine immediate-release (IR): efficacy and safety. Presented at: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14–17, 2003; Chi-cago, IL, USA. Abstract H843.
   Google Scholar
• Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002;3:371–378.
   PubMedGoogle Scholar
• Cina CS, Clase CM. The Illness Intrusiveness Rating Scale: a measure of severity in individuals with hyperhidrosis. Qual Life Res. 1999;8:693–698.
   PubMed Web of Science ®Google Scholar
• Clayson DJ, Wild DJ, Quarterman P, et al. A compara-tive review of health-related quality of life measures for use in HIV/AIDS clinical trials. Pharmacoeconomics. 2006; 24:751–765.
   PubMed Web of Science ®Google Scholar
• Cote JK, Godin G. Efficacy of interventions in improving adherence to antiretroviral therapy. Int J AIDS. 2005;16: 335–343.
   PubMed Web of Science ®Google Scholar
• Portsmouth SD, Osorio J, McCormick K, et al. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med. 2005;6:185–190.
   PubMed Web of Science ®Google Scholar
• Munakata J, Benner JS, Becker S, et al. Clinical and eco-nomic outcomes of nonadherence to highly active antiret-roviral therapy in patients with human immunodeficiency virus. Med Care. 2006;44:893–899.
   PubMed Web of Science ®Google Scholar
• Eldred LJ, Wu AW, Chaisson RE, et al. Adherence to anti-retroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum RetroyiroL 1998;18:117–125.
   PubMed Web of Science ®Google Scholar
• Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 2001;161:1962–1968.
   PubMed Web of Science ®Google Scholar
• Kerr T, Walsh J, Lloyd-Smith E, et al. Measuring adher-ence to highly active antiretroviral therapy: implications for research and practice. Curr HIV/AIDS Rep. 2005;2: 200–205.
   PubMedGoogle Scholar
• Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment tech-nique. JAMA. 1989;261:3273–3277.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adher-ence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibi-tors. Clin Infect Dis. 2005;40:158–163.
   PubMed Web of Science ®Google Scholar
• Arpinelli F, Bamfi F. The FDA guidance for industry on PROs: the point of view of a pharmaceutical company. Health Qual Life Outcomes. 2006;4:85–89.
   PubMed Web of Science ®Google Scholar
• Campo R, Cohen C, Grimm K, et al. Simplification from protease inhibitor- to efavirenz-based highly active antiret-roviral therapy improves quality of life and adherence with low rates of virologic failure. Manuscript in preparation.
   Google Scholar
• Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev. 2006;8:191–203.
   PubMed Web of Science ®Google Scholar
• Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143:714–721.
   PubMed Web of Science ®Google Scholar